Ambry Genetics Adds Certification of Roche NimbleGen CGH, DNA Methylation, Gene Expression, and ChIP-chip to Service Portfolio
Madison, WI, USA, 19 April 2011
Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for NimbleGen Comparative Genomic Hybridization (CGH), Chromatin Immunoprecipiation-on-chip (ChIP-chip), DNA Methylation and Gene Expression. The addition of these applications means Ambry Genetics is now certified on all Roche NimbleGen applications, the first of its kind in the United States. They will process customer samples for copy number variation, DNA methylation analysis, gene expression analysis, and DNA-protein interactions and chromatin structure. They have been certified at their lab in Aliso Viejo, CA using the complete NimbleGen Dual- and Single-Color microarray workflow which includes the high-resolution MS 200 Microarray Scanner. Ambry Genetics has passed a rigorous certification test plan with precise experimental standards to add the certification of these applications to their service portfolio.
“In addition to providing NimbleGen Sequence Capture services, we are excited to offer microarray services as a certified service provider for all applications including array CGH, gene expression, methylation and ChIP-chip. The endorsement of Ambry as the first CSP in the world for the entire NimbleGen array portfolio emphasizes the mutual commitment to quality data and expert support,“ said Dr. Anja Kammesheidt, Chief Scientific Officer at Ambry Genetics.
“Roche NimbleGen is extremely pleased that Ambry Genetics, our first Certified Service Provider in the United States, has now been certified to provide services on all of our array applications which use the robust NimbleGen MS 200 Scanner workflow. This now effectively provides researchers with a complete and single source service solution from a premier service provider. We look forward to our collaboration with Ambry Genetics to further drive innovation with the research market and expand the use of NimbleGen products to end customers via a certified service provider" said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.
For more information about Roche NimbleGen, please visit www.nimblegen.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
About Ambry Genetics
Ambry Genetics is a CAP-accredited, CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Established in 2000, it is a recognized leader in diagnostic and contract genomic services. Ambry specializes in the application of new technologies to molecular diagnostics and genetics research. To learn more about Ambry Genetics, visit www.ambrygen.com
For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN is a trademark of Roche.
Other brands or product names are trademarks of their respective holders.